Chemokine receptor antagonists: overcoming developmental hurdles

Area of Science:

• Immunology and Pharmacology
• Drug Discovery and Development

Background:

• Chemokine receptors are implicated in autoimmune diseases, inflammation, and viral infections.
• Despite their role, chemokine receptor antagonists have largely failed in clinical trials, except for CCR5 antagonists in HIV treatment.

Purpose of the Study:

• To review recent clinical trial failures of chemokine receptor antagonists.
• To explore the underlying reasons for these failures.
• To propose novel therapeutic strategies for targeting chemokine receptors.

Main Methods:

• Review of recent clinical trial data for chemokine receptor antagonists.
• Analysis of potential reasons for therapeutic failure, including animal model limitations and target redundancy.
• Exploration of polypharmacology as a potential therapeutic approach.

Main Results:

• Several clinical trials for chemokine receptor antagonists have failed to demonstrate efficacy.
• Key challenges identified include poor predictability of animal models and functional redundancy of chemokine receptor pathways.
• Polypharmacology, targeting multiple receptors simultaneously, is presented as a promising alternative strategy.

Conclusions:

• The development of effective therapeutics targeting chemokine receptors has been hindered by significant challenges.
• Addressing target redundancy and improving preclinical model predictability are crucial for future drug development.
• Polypharmacology offers a novel and potentially more effective approach to harness the therapeutic potential of chemokine receptor modulation.